🦠
MicroDAO Whitepaper
  • MICRO: Funding the next generation of AMR Solutions: Antimicrobials, Diagnostics, and Vaccines
    • Executive Summary
    • The AMR Challenge
      • Understanding Antimicrobial Resistance
      • The Human Innovation Gap
      • Investments into AMR solutions
    • microDAO: A Community-Driven Solution to Tackle AMR
      • Vision and Mission
      • Operational Framework
      • Structure of microDAO
        • Core Team
        • Community Members
        • Token Holders
        • Working Groups
        • Service Providers
        • Partners
        • End users of solutions and funding offered by microDAO
    • DAO Way of Working
    • microDAO’s Flywheel for Impact and Revenue: Community Tools and Workflows
      • Evidence Generation & Decision Support Tools
      • R&D Acceleration Tools
    • microDAO Revenue Streams: Building Sustainable Impact
    • Fund Allocation Strategy for liquid funds available in the DAO treasury
      • Strategic Priority Areas
        • Early-Stage Research Development
        • Clinical Development Support
        • Equitable Access Programmes
        • Infrastructure and Tools
        • Operational Sustainability
    • Impact and Future Outlook
Powered by GitBook
On this page
  1. MICRO: Funding the next generation of AMR Solutions: Antimicrobials, Diagnostics, and Vaccines
  2. Fund Allocation Strategy for liquid funds available in the DAO treasury
  3. Strategic Priority Areas

Equitable Access Programmes

A large portion of our funds supports equitable access to developed solutions, focusing on technology transfer to manufacturers in low- and middle-income countries (LMICs). microDAO will fund pilot programmes for implementing new antimicrobials and diagnostics in resource-limited settings, while supporting local capacity building in AMR management.

PreviousClinical Development SupportNextInfrastructure and Tools

Last updated 5 months ago